Exhibit 99.1

IN THE UNITED STATES BANKRUPTCY COURT

FOR THE DISTRICT OF DELAWARE


- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -	x
	:
In re:	:	Chapter 11
	:
SAVIENT PHARMACEUTICALS, INC.,	:	Case No. 13-12680 (MFW)
et al.,	:
	:	Jointly Administered
Debtors.¹	:
	:
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -	x

NOTICE OF FILING OF DEBTORS’ MONTHLY OPERATING REPORT

FOR THE PERIOD OF FEBRUARY 1, 2014 THROUGH FEBRUARY 28, 2014

PLEASE TAKE NOTICE that the debtors and debtors-in-possession in the above-captioned cases

(collectively, the “Debtors”) filed today the Debtors’ Monthly Operating Report for the Period of February 1,

2014 through February 28, 2014, a copy of which is attached hereto as Exhibit A (the “Monthly Operating

Report”).

Dated: Wilmington, Delaware

March 20, 2014

COLE, SCHOTZ, MEISEL, FORMAN

& LEONARD, P.A.

/s/ David R. Hurst

David R. Hurst (I.D. No. 3743)

J. Kate Stickles (I.D. No. 2917)

500 Delaware Avenue, Suite 1410

Wilmington, Delaware 19801

Telephone: (302) 652-3131

Facsimile: (302) 652-3117

Counsel for Debtors and Debtors-in-Possession

The Debtors and the last four digits of their respective taxpayer identification numbers are as follows: Savient Pharmaceuticals, Inc. (3811); and Savient Pharma Holdings, Inc. (0701). The address of the Debtors’ corporate headquarters is 400 Crossing Boulevard, 4^thFloor, Bridgewater, New Jersey 08807.

EXHIBIT A

Monthly Operating Report

UNITED STATES BANKRUPTCY COURT

FOR THE DISTRICT OF DELAWARE


In re: Savient Pharmaceuticals, Inc., et al		Case No.13-12680 (MFW)
		Reporting Period: February 1, 2014 - February 28, 2014

MONTHLY OPERATING REPORT


REQUIRED DOCUMENTS	Form No.	Document Attached	Explanation Attached**	Affidavit/Supplement Attached**
Schedule of Cash Receipts and Disbursements	MOR-1	Yes
Bank Reconciliation (or copies of debtor’s bank reconciliation	MOR-1a	Yes
Schedule of Professional Fees Paid	MOR-1b	Yes
Copies of bank statements		No	Yes
Cash disbursements journals		No	Yes
Statement of Operations	MOR-2	Yes
Balance Sheet	MOR-3	Yes
Status of Postpetition Taxes	MOR-4	Yes
Copies of IRS Form 6123 or payment receipt		No	Yes
Copies of tax returns filed during reporting period		No	Yes
Summary of Unpaid Postpetition Debts	MOR-4	Yes
Listing of aged accounts payable	MOR-4	Yes
Accounts Receivable Reconciliation and Aging	MOR-5	Yes
Debtor Questionnaire	MOR-5	Yes

**	Explaination and Affidavit/Supplement are attached as a part of the Company’s General Notes

I declare under penalty of perjury (28 U.S.C. Section 1746) that this report and the attached documents are true and correct to the best of my knowledge and belief.



Signature of Debtor				Date


Signature of Joint Debtor				Date

/s/ Mathew C. Bazley				March 20, 2014
Signature of Authorized Individual*				Date

Mathew C. Bazley				Chief Liquidation Officer, President and Secretary
Printed Name of Authorized Individual				Title of Authorized Individual

MOR_Cover

MOR COVER

(04/07)


In re: Savient Pharmaceuticals, Inc. et al.		Case Nos. 13-12680, 13-12681 (MFW)
		Reporting Period: 2/1/2014 - 2/28/2014

NOTES TO THE MONTHLY OPERATING REPORT

General Notes

Debtors. Debtor Savient Pharmaceuticals, Inc. is referred to herein as “Savient” or “SPI,” and Debtor Savient Pharma Holdings, Inc. is referred to herein as “SPHI.”

Debtor-in-Possession Financial Statements. The Debtors’ financial statements and supplemental information contained herein are unaudited, preliminary and may not comply with generally accepted accounting principles in the United States of America (“U.S. GAAP”) in all material respects.

Accounting Standards Codification, (“ASC”) 852-10, Reorganizations, which incorporated the guidance in American Institute of Certified Public Accountants Statement of Position 90-7, Financial Reporting by Entities in Reorganization under the Bankruptcy Code, (SOP 90-7), is applicable to companies in chapter 11 and generally does not change the manner in which financial statements are prepared. It does require, however, that the financial statements for periods subsequent to the filing of the chapter 11 petition distinguish transactions and events that are directly associated with the reorganization from the ongoing operations of business.

The Debtors’ financial statements contained herein have been prepared in accordance with the guidance in ASC 852-10. The unaudited financial statements have been derived from the books and records of the Debtors. This information, however, has not been subject to procedures that would typically be applied to financial information presented in accordance with U.S GAAP, and upon the application of such procedures, the Debtors believe that the financial information could be subject to changes, and these changes could be material. The information furnished in this report includes primarily normal recurring adjustments, but does not include all of the adjustments that would be typically made in accordance with U.S. GAAP.

The results of operations contained herein are not necessarily indicative of results that are expected from any other period or for the full year and may not necessarily reflect the combined results of operations, financial position and cash flows of the Debtors in the future.

Intercompany Transactions. Receivables and payables between the Debtors and/or Non-Debtors have not been eliminated.

Liabilities Subject to Compromise. As a result of the chapter 11 filings, the payment of prepetition indebtedness is subject to compromise or other treatment under a plan of reorganization or liquidation.

The determination of how liabilities ultimately will be settled and treated cannot be made until the United States Bankruptcy Court for the District of Delaware approves a chapter 11 plan of reorganization or liquidation. Accordingly, the ultimate amount of such liabilities is not determinable at this time. Revenues, expenses, realized gains and losses and provisions for losses that can be directly associated with the reorganization and restructuring of the business must be reported separately as reorganization items in the Debtors’ statements of operations.

The Debtors’ balance sheets, in addition, must distinguish prepetition liabilities subject to compromise from both those prepetition liabilities that are not subject to compromise and from postpetition liabilities. Liabilities that may be affected by a plan of reorganization or liquidation must be reported at the amounts expected to be allowed, even if they may be settled for lesser amounts. In addition, cash provided by reorganization items must be disclosed separately in the Debtors’ statements of cash flows. The amounts currently classified as liabilities subject to compromise are preliminary and may be subject to future adjustments depending on Court actions, further developments with respect to disputed claims, determinations of the secured status of certain claims, the values of any collateral securing such claims, rejection of executory contracts, continued reconciliation and other events.

While in bankruptcy, the Debtors expect their financial results to continue to be volatile as asset impairments, asset dispositions, contract terminations and rejections and claims assessments may significantly impact the Debtors’ financial statements. As a result, the Debtors’ historical financial performance is likely not indicative of its financial performance after the date of the chapter 11 filings.

Notes to MOR-1a

Copies of Bank Statements and Cash Disbursements Journals. The copies of the Debtors’ bank statements and cash disbursement journals are voluminous and not included herein, but will be provided upon request.

Notes to MOR-4

Copies of IRS Form 6123; Tax Returns. To be provided upon request.

Savient MOR-4. The postpetition accounts payable reported for Debtor Savient Pharmaceuticals, Inc. represent trade vendor invoices that have been entered into the Debtor’s accounts payable system and do not include accruals for invoices not yet received or approved.


	BANK ACCOUNT ACTIVITY FOR THE MONTH ENDED February 28, 2014																					CUMULATIVE FILING TO DATE OCTOBER 15, 2013 THROUGH FEBRUARY 28, 2014

	PNC			AR Lockbox			Fidelity		Wells Fargo		Wells Fargo Utilities		PNC - LOC (secure LOC)		PNC - LOC (covers fees)		Petty Cash		TOTAL			TOTAL
CASH BEGINNING OF MONTH	$	6,717,825		$	1,003,474		$	-	$	6,209,254	$	14,228	$	1,304,340	$	150,222	$	1,000	$	15,400,343		$	12,255,382

RECEIPTS
TRANSFER FROM SUB (SPHI)		-			-			-		-		-						-		-			13,700,356
ACCOUNTS RECEIVABLE		10,937			1,030,335			-		-		-						-		1,041,272			8,242,214
TRANSFERS (FROM FIDELITY MM)		-			-			-		-		-						-		-			383,692
STATE MEDICAID REFUNDS					-			-		-		-						-		-			98,009
REFUNDS FROM VENDORS		-			-			-		-		-						-		-			84,006
ACTAVIS-SALES (oxandrolone royalty)		56,283			-			-		-		-						-		56,283			125,823
KINERET CO-PROMOTE REVENUE		-			-			-		-		-						-		-			61,859
TRANSFER FROM OPERATING ACCOUNT		-			-			-		-		-						-		-			14,228
COBRA PAYMENTS FROM EMPLOYEES		3,957			-			-		-		-						-		3,957			35,452
AMEX RECEIPTS FROM EMPLOYEES		1,565			-			-		-		-						-		1,565			9,773
RECEIPTS FROM EMPLOYEE ADVANCES		-			-			-		-		-						-		-			500
EQUIPMENT PURCHASES BY EMPLOYEES		-			-			-		-		-						-		-			400
DIVIDENDS ON MONEY MARKET ACCOUNT		-			-			-		-		-						-		-			123
INVESTMENT INCOME FROM CD PORFOLIO		-			-			-		-		-						-		-			576
Proceeds from Sales to Crealta		-			-			-		-		-						-		-			116,282,138
		-			-			-		-		-						-		-			-
TOTAL RECEIPTS	$	72,742		$	1,030,335		$	-	$	-	$	-	$	-	$	-	$	-	$	1,103,077		$	139,039,150

DISBURSEMENTS
PAYMENTS TO NOTE HOLDERS		100,303			1,490,000			-		-		-						-		1,590,303			126,129,253
NET PAYROLL		64,010			-			-		-		-						-		64,010			3,710,928
PROFESSIONAL FEES		1,461,932			-			-		-		-						-		1,461,932			4,281,039
CONSULTANT FEES		17,981																		17,981			27,277
VENDOR PAYMENTS		69,168			-			-		-		-						-		69,168			1,454,479
EMPLOYEE BENEFITS (401K & Health)		-			-			-		-		-						-		-			578,218
STATE AGENCIES AND TAX PAYMENTS		-			-			-		-		-						-		-			453,007
TRANSFERS TO OPERATING ACCOUNT		-			-			-		-		-						-		-			383,692
RENT		22,246			-			-		-		-						-		22,246			406,948
CONCUR (employee expenses)		-			-			-		-		-						-		-			270,885
PAYMENTS TO BOARD OF DIRECTORS		67			-			-		-		-						-		67			178,203
FUNDING FOR CO-PAY PROGRAM		-			-			-		-		-						-		-			36,872
AMERICAN EXPRESS (employee expenses)		235			-			-		-		-						-		235			28,988
AMERIFLEX (flex spending)		873			-			-		-		-						-		873			29,504
TRANSFER TO WELLS FARGO UTILITY ACCOUNT		-			-			-		-		-						-		-			14,228
EMPLOYEE EDUCATION REIMBURSEMENT		-			-			-		-		-						-		-			12,985
STORAGE AND WAREHOUSE (INVENTORY)		-			-			-		-		-						-		-			4,995
BANK FEES		483			-			-		-		-						-		483			14,705
SHIPPING AND DELIVERY		60			-			-		-		-						-		60			2,265
																							-
TOTAL DISBURSEMENTS	$	1,737,358		$	1,490,000		$	-	$	-	$	-	$	-	$	-	$	-	$	3,227,358		$	138,018,470

NET CASH FLOW	$	(1,664,616	)	$	(459,665	)	$	-	$	-	$	-	$	-	$	-	$	-	$	(2,124,282	)	$	1,020,680
(RECEIPTS LESS DISBURSEMENTS)		-			-			-		-		-		-		-		-		-			-

CASH - END OF MONTH	$	5,053,209		$	543,809		$	-	$	6,209,254	$	14,228	$	1,304,340	$	150,222	$	1,000	$	13,276,062		$	13,276,062
* COMPENSATION TO SOLE PROPRIETORS FOR SERVICES RENDERED TO BANKRUPTCY ESTATE


DISBURSEMENTS FOR CALCULATING U.S. TRUSTEE QUARTERLY FEES: (FROM CURRENT MONTH ACTUAL COLUMN)											FOR THE MONTH ENDED FEBRUARY 28, 2014		FOR THE MONTH ENDED JANUARY 31, 2014		FOR THE MONTH ENDED December 31, 2013		FOR THE MONTH ENDED NOVEMBER 30, 2013		FOR THE PERIOD OCTOBER 15, 2013 THROUGH OCTOBER 31, 2013			CUMMULATIVE FILING TO DATE OCTOBER 15, 2013 THROUGH FEBRUARY 28, 2014
TOTAL DISBURSEMENTS											$	3,227,358	$	121,139,406	$	2,492,701	$	2,396,428	$	8,762,577		$	138,018,470
LESS: TRANSFERS TO DEBTOR IN POSSESSION ACCOUNTS												-				-		384,867		13,053			397,920
LESS: PAYMENT OF U.S. TRUSTEE FEES														13,325									13,325
PLUS: ESTATE DISBURSEMENTS MADE BY OUTSIDE SOURCES (i.e., from escrow accounts)												-		-		-		-		-			-
												-		-		-		-		-			-
TOTAL DISBURSEMENTS FOR CALCULATING U.S. TRUSTEE QUARTERLY FEES											$	3,227,358	$	121,139,406	$	2,492,701	$	2,011,561	$	8,749,524		$	137,607,225

SAVIENT_MOR_1

FORM MOR-1

(04/07)


In re: Savient Pharmaceuticals, Inc., et a		Case No. 13-12680 (MFW)
Debtor		Reporting Period: February 1, 2014 - February 28, 2014

SPHI (13-12681): SCHEDULE OF CASH RECEIPTS AND DISBURSEMENTS


	BANK ACCOUNT ACTIVITY FOR THE MONTH ENDED FEBRUARY 28, 2014			BANK ACCOUNT ACTIVITY FOR THE MONTH ENDED JANUARY 31, 2014		BANK ACCOUNT ACTIVITY FOR THE MONTH ENDED DECEMBER 31, 2013		BANK ACCOUNT ACTIVITY FOR THE MONTH ENDED NOVEMBER 30, 2013		BANK ACCOUNT ACTIVITY FOR THE PERIOD OCTOBER 15, 2013 THROUGH OCTOBER 31, 2013			CUMULATIVE FILING TO DATE OCTOBER 15, 2013 THROUGH FEBRUARY 28, 2014

		PNC			PNC		PNC		PNC		PNC			ACTUAL
CASH BEGINNING OF MONTH	$	3,241,587		$	3,241,587	$	3,241,584	$	3,241,584	$	16,941,887		$	16,941,887

RECEIPTS
DIVIDENDS ON MONEY MARKET ACCOUNT		-			-		3		-		73			76
		-			-		-		-		-			-
TOTAL RECEIPTS	$	-		$	-	$	3	$	-	$	73		$	76

DISBURSEMENTS
TRANSFERS TO SAVIENT OPERATING ACCOUNT		-			-		-		-		13,700,356			13,700,356
BANK FEES		-			-		-		-		20			20
VENDOR PAYMENTS		945			-		-		-		-			945
TOTAL DISBURSEMENTS	$	945		$	-	$	-	$	-	$	13,700,376		$	13,701,321

NET CASH FLOW	$	(945	)	$	-	$	3	$	-	$	(13,700,303	)	$	(13,701,245	)
(RECEIPTS LESS DISBURSEMENTS)		-			-		-		-		-			-

CASH - END OF MONTH	$	3,240,642		$	3,241,587	$	3,241,587	$	3,241,584	$	3,241,584		$	3,240,642


DISBURSEMENTS FOR CALCULATING U.S. TRUSTEE QUARTERLY FEES: (FROM CURRENT MONTH ACTUAL COLUMN)	CURRENT MONTH FEBRUARY 28, 2014			CURRENT MONTH JANUARY 31, 2014		CURRENT MONTH DECEMBER 31, 2013		FOR THE MONTH ENDED NOVEMBER 30, 2013		FOR THE PERIOD OCTOBER 15, 2013 THROUGH OCTOBER 31, 2013			CUMMULATIVE FILING TO DATE OCTOBER 15, 2013 THROUGH FEBRUARY 28, 2014
TOTAL DISBURSEMENTS	$	945		$	-	$	-	$	-	$	13,700,376		$	13,701,321
LESS: TRANSFERS TO DEBTOR IN POSSESSION ACCOUNTS		-			-		-		-		-			-
LESS: TRANSFERS BETWEEN ACCOUNTS		-			-		-		-		13,700,356			13,700,356
		-			-		-		-		-			-
TOTAL DISBURSEMENTS FOR CALCULATING U.S. TRUSTEE QUARTERLY FEES	$	945		$	-	$	-	$	-	$	20		$	965

SPHI_MOR_1

FORM MOR-1

(04/07)


In re: Savient Pharmaceuticals, Inc., et al		Case No. 13-12680 (MFW)
Debtor		Reporting Period: February 1, 2014 - February 28, 2014

SAVIENT (13-12680): BANK RECONCILIATIONS


		PNC				PNC Lockbox			Fidelity			Wells Fargo			Wells Fargo Utilities			PNC - Letter of Credit (secure LOC)			PNC - Letter Of Credit (covers fees)			Petty Cash
	#				#			#			#			#			#			#			#
BALANCE PER BOOKS		$	5,053,209			$	543,809		$	-		$	6,209,254		$	14,228		$	1,304,340		$	150,222		$	1,000

BANK BALANCE		$	5,121,340			$	543,809		$	-		$	6,209,254		$	14,228		$	1,304,340		$	150,222		$	-
(+) DEPOSITS IN TRANSIT (ATTACH LIST)			-				-			-			-			-			-			-			-
(-) OUTSTANDING CHECKS (ATTACH LIST)			(68,131	)			-			-			-			-			-			-			-
OTHER (ATTACH EXPLANATION)			-				-			-			-			-			-			-			-
ADJUSTED BANK BALANCE *		$	5,053,209			$	543,809		$	-		$	6,209,254		$	14,228		$	1,304,340		$	150,222		$	-
* Adjusted bank balance must equal
balance per books

DEPOSITS IN TRANSIT	Date		Amount		Date		Amount	Date		Amount	Date		Amount	Date		Amount	Date		Amount	Date		Amount	Date		Amount
NONE


CHECKS OUTSTANDING	Ck. #		Amount		Ch. #		Amount	Ch. #		Amount	Ck. #		Amount	Ck. #		Amount	Ck. #		Amount	Ck. #		Amount	Ck. #		Amount

Total Outstanding Checks		$	68,132

Savient MOR_1a

FORM MOR-1a

(04/07)


In re: Savient Pharmaceuticals, Inc., et al		Case No. 13-12680 (MFW)
Debtor		Reporting Period: February 1, 2014 - February 28, 2014

SPHI (13-12681): BANK RECONCILIATIONS


	PNC
	#
BALANCE PER BOOKS		$	3,240,642

BANK BALANCE		$	3,240,642
(+) DEPOSITS IN TRANSIT (ATTACH LIST)			-
(-) OUTSTANDING CHECKS (ATTACH LIST)			-
OTHER (ATTACH EXPLANATION)			-
ADJUSTED BANK BALANCE *		$	3,240,642
* Adjusted bank balance must equal
balance per books

DEPOSITS IN TRANSIT	Date		Amount
NONE

CHECKS OUTSTANDING	Ck. #		Amount
NONE

SPHI MOR_1a

FORM MOR-1a

(04/07)

MOR-1a (Addendum)

Savient (13-12680): Open Bank Accounts as of February 28, 2014


Account number	Bank	Type	Book Balance

xxxxxx9201	Wells Fargo	U.S. Treasury Money Market Fund	$	6,209,254
xxxxxx5904	Wells Fargo	Utilities (Bankruptcy account)	$	14,228
xxxxxx5687	PNC	Savient Inc Operating Account	$	5,053,209
xxxxxx1019	PNC	AR Lockbox	$	543,809
xxxxxx2019	PNC	Letter of Credit (Secure LOC)	$	1,304,340
xxxxxx2548	PNC	Letter of Credit (Covers fees)	$	150,222

MOR-1a (Addendum)

SPHI (13-12681): Open Bank Accounts as of February 28, 2014


Account number	Bank	Type	Book Balance

xxxxxx6418	PNC	SPHI Operating Account	$	3,240,642


		In re: Savient Pharmaceuticals, Inc., et al				Case No. 13-12680 (MFW)
		Debtor				Reporting Period: February 1, 2014 - February 28, 2014

SAVIENT (13-12680): SCHEDULE OF PROFESSIONAL FEES AND EXPENSES PAID

Amount

Check

Amount Paid

Cumulative-To-Date

Payee

Period Covered

Approved

Payor

Number

Date

Fees

Expenses

Fees

Expenses

Mary Bordeaux Consulting

10/15-10/31/2013

N/A

Savient Pharmaceuticals, Inc.

67595

11/21/2013

600

Mary Bordeaux Consulting

11/1-11/30/2013

N/A

Savient Pharmaceuticals, Inc.

67651

12/18/2013

1,000

Mary Bordeaux Consulting

12/1-12/31/2013

N/A

Savient Pharmaceuticals, Inc.

67724

1/9/2014

800

Mary Bordeaux Consulting

1/1-31/2014

N/A

Savient Pharmaceuticals, Inc.

67796

2/10/2014

1,050

3,450

The Garden City Group,

Advance

N/A

Savient Pharmaceuticals, Inc.

Wire

11/4/2013

63,400

6,600

The Garden City Group,

Advance

N/A

Savient Pharmaceuticals, Inc.

Wire

11/5/2013

18,000

7,000

The Garden City Group,

Advance

N/A

Savient Pharmaceuticals, Inc.

Wire

12/3/2013

80,000

The Garden City Group,

10/15-11/30/2013

N/A

Savient Pharmaceuticals, Inc.

Wire

1/3/2014

288,234

57,006

The Garden City Group,

Advance

N/A

Savient Pharmaceuticals, Inc.

Wire

2/7/2014

6,000

19,000

The Garden City Group,

12/1-31/2013

N/A

Savient Pharmaceuticals, Inc.

Wire

2/13/2014

72,527

42,313

528,161

131,918

Weiss, Rifkind,

10/14-10/31/2013

N/A

Savient Pharmaceuticals, Inc.

Wire

11/19/2013

95,901

1,878

Weiss, Rifkind,

11/1-11/30/2013

N/A

Savient Pharmaceuticals, Inc.

Wire

12/23/2013

189,132

5,669

Weiss, Rifkind,

12/1-12/31/2013

N/A

Savient Pharmaceuticals, Inc.

Wire

1/27/2014

237,592

4,751

Weiss, Rifkind,

1/1-31/2014

N/A

Savient Pharmaceuticals, Inc.

Wire

2/18/2014

120,274

740

642,899

13,038

Maples and Calder

11/1-11/29/2013

N/A

Savient Pharmaceuticals, Inc.

Wire

12/18/2013

14,732

14,732

Shannon, Gracy and Ratlif

10/15-10/26/2013

N/A

Savient Pharmaceuticals, Inc.

Wire

12/18/2013

564

Shannon, Gracy and Ratlif

11/1-11/30/2013

N/A

Savient Pharmaceuticals, Inc.

67736

1/9/2014

1,595

141

Shannon, Gracy and Ratlif

12/1-25/2013

N/A

Savient Pharmaceuticals, Inc.

67802

2/10/2014

458

2,617

212

The Pine Hill Group

10/15-11/30/2013

N/A

Savient Pharmaceuticals, Inc.

Wire

12/13/2013

62,530

The Pine Hill Group

12/1-12/14/2013

N/A

Savient Pharmaceuticals, Inc.

Wire

12/18/2013

15,263

The Pine Hill Group

12/15/2013-1/17/2014

N/A

Savient Pharmaceuticals, Inc.

Wire

1/9/2014

28,788

The Pine Hill Group

1/1-1/17/2014

N/A

Savient Pharmaceuticals, Inc.

Wire

1/21/2014

4,625

The Pine Hill Group

1/20-1/24/2014

N/A

Savient Pharmaceuticals, Inc.

Wire

1/30/2014

5,828

The Pine Hill Group

1/27-1/31/2014

N/A

Savient Pharmaceuticals, Inc.

Wire

2/6/2014

5,273

The Pine Hill Group

2/3-2/14/2014

N/A

Savient Pharmaceuticals, Inc.

Wire

2/18/2014

4,995

127,301

Cole, Schotz, Meisel, Forman & Leonard, P.A.

10/14-11/30/2013

N/A

Savient Pharmaceuticals, Inc.

Wire

1/28/2014

284,120

2,514

Cole, Schotz, Meisel, Forman & Leonard, P.A.

12/1-31/2013

N/A

Savient Pharmaceuticals, Inc.

Wire

2/13/2014

248,629

1,293

532,749

3,808

Deloitte Tax LLP

10/14-11/25/2013

N/A

Savient Pharmaceuticals, Inc.

67710

1/9/2014

7,500

300

Deloitte Tax LLP

11/25-12/16/2013

N/A

Savient Pharmaceuticals, Inc.

67710

1/9/2014

18,670

747

26,170

1,047

Joele Frank Wilkinson Brimmer

10/11-10/31/2013

N/A

Savient Pharmaceuticals, Inc.

67719

1/9/2014

25,772

6,219

Joele Frank Wilkinson Brimmer

11/01-11/30/2013

N/A

Savient Pharmaceuticals, Inc.

67719

1/9/2014

5,101

385

Joele Frank Wilkinson Brimmer

12/01-12/31/2013

N/A

Savient Pharmaceuticals, Inc.

67756

1/17/2014

21,694

9,064

52,567

15,667

Kaufman Dolowich & Voluck, LLP

10/14-10/31/2013

N/A

Savient Pharmaceuticals, Inc.

67720

1/9/2014

2,075

Kaufman Dolowich & Voluck, LLP

11/01-11/22/2013

N/A

Savient Pharmaceuticals, Inc.

67720

1/9/2014

4,171

6,246

Kramer, Levin, Naftalis & Frankel, LLP

10/14-11/30/2013

N/A

Savient Pharmaceuticals, Inc.

Wire

2/7/2014

42,878

Kramer, Levin, Naftalis & Frankel, LLP

12/1-31/2013

N/A

Savient Pharmaceuticals, Inc.

Wire

2/13/2014

44,591

3,754

44,591

46,632

Lowenstein Sandler, LLP

10/14-10/31/2013

N/A

Savient Pharmaceuticals, Inc.

67723

1/9/2014

1,851

Lowenstein Sandler, LLP

11/1-11/30/2013

N/A

Savient Pharmaceuticals, Inc.

67723

1/9/2014

2,897

Lowenstein Sandler, LLP

12/1-12/31/2013

N/A

Savient Pharmaceuticals, Inc.

67783

1/31/2014

131

Lowenstein Sandler, LLP

01/1-31/2014

N/A

Savient Pharmaceuticals, Inc.

67832

2/27/2014

3,151

8,030

Skadden, Arps, Slate, Meagher & Flom LLP

10/14-11/30/2013

N/A

Savient Pharmaceuticals, Inc.

Wire

1/28/2014

1,185,074

19,552

Skadden, Arps, Slate, Meagher & Flom LLP

12/1-31/2013

N/A

Savient Pharmaceuticals, Inc.

Wire

2/27/2014

788,907

54,617

1,973,981

74,169

Sterne, Kessler, Goldstein, Fox

11/1-11/30/2013

N/A

Savient Pharmaceuticals, Inc.

67738

1/9/2014

1,958

Sterne, Kessler, Goldstein, Fox

12/1-31/2013

N/A

Savient Pharmaceuticals, Inc.

67803

2/10/2014

852

627

2,810

627

Young Conaway Stargatt & Taylor, LLP

10/14-11/30/2013

N/A

Savient Pharmaceuticals, Inc.

Wire

1/14/2014

27,001

616

27,001

616

SAVIENT MOR_1b

FORM MOR-1b

(04/07)


		In re: Savient Pharmaceuticals, Inc., et al				Case No. 13-12680 (MFW)
		Debtor				Reporting Period: February 1, 2014 - February 28, 2014

SPHI (13-12681): SCHEDULE OF PROFESSIONAL FEES AND EXPENSES PAID

Amount

Check

Amount Paid

Year-To-Date

Payee

Period Covered

Approved

Payor

Number

Date

Fees

Expenses

Fees

Expenses

No professional fee payments were made by the Debtor during the Reporting Period 2/1/14 through 2/28/14

SPHI MOR_1b

FORM MOR-1b

(04/07)


In re: Savient Pharmaceuticals, Inc., et al				Case No. 13-12680 (MFW)
Debtor				Reporting Period: February 1, 2014 - February 28, 2014

SAVIENT (13-12680): STATEMENT OF OPERATIONS

(Income Statement)


				Cumulative
	For The			Filing to Date
	Month Ended			October 15, 2013
	February 28,			Through
REVENUES	2014			February 28, 2014
Gross Revenues	$	-		$	10,307,196
Less: Gross-to-Net Adjustments		-337,89	9	$	3,092,285
Net Revenue	$	337,899		$	7,214,911
COST OF GOODS SOLD
Beginning Inventory	$	-		$	4,516,751
Add: Purchases		-			-
Add: Cost of Labor		-			-
Add: Other Costs (attach schedule)		-			-
Less: Ending Inventory	$	-		$	3,308,559
Change in Inventory		-			1,208,192
Reclass Sales to Gain/Loss		-			(1,012,971	)
					-
Add: Royalties (MVP & DUKE)		-			451,915
Add: Royalties (Office of the Chief Scientist of Israel)		-			177,122
Add: Management fee allocation to COGS		-			93,375
Add: Stability testing		-			79,331
Add: Distribution fees		-			75,982
Cost of Goods Sold	$	-		$	1,072,946
Gross Profit	$	337,899		$	6,141,965
OPERATING EXPENSES
Research and Development Related Expenses:
Investigator grants	$	-		$	150,000
QC & Stability testing		-			60,360
CRO costs		-			111,312
Pharmacovigilance		-			54,744
Process development and Improvement		-			23,878
IP Related			0		12,836
Central labs			0		8,958
REMS Communication and assessment		-			7,590
Publications			0		6,891
Research			0		1,407
Medical education			0		-
Total Research and Development Related Expenses	$	-		$	437,976
				$	-
Selling and Marketing Related Expenses:					-
Pricing and reimbursement	$	-		$	171,166
Exhibit booth		-			69,019
Speakers programs		-			52,882
Maketing and other promotional activity		-			61,261
Medical meetings and symposia		-			38,167
Medical education		-			26,193
Market research		-			5,585
Publications		-			78
Total Selling and Marketing Related Expenses	$	-		$	424,351
				$	-
General and Administrative Related Expenses:					-
Compensation and related benefits and taxes	$	61,478		$	3,881,739
Insurance (amortization of prepaid insurance)		166,397			976,540
Share-based compensation (SFAS 123-R expense)		33,000			686,522
Sales force commissions		-			351,582
Occupancy		9,667			434,750
Travel and entertainment		-			235,641
Accrued Board of Directors’ cash payments & meeting fees		14,234			187,288
Outside consulting services		-			137,126
Corporate communications and investor relations		-			118,554
Legal		8,586			85,561
Licenses and information		-			58,090
Communications (Utilities)		1,133			47,351
General expenses and office supplies		40,637			94,485
Postage and Shipping		364			6,405
Total General and Administrative Related Expenses:	$	335,496		$	7,301,634
Total Operating Expenses Before Depreciation	$	335,496		$	8,163,961
Depreciation and amortization		-			110,582
Net Loss Before Other Income & Expenses	$	2,403		$	(2,132,578	)
					-
OTHER INCOME AND (EXPENSES)					-
Dividend/Interest income	$	58		$	757
Interest Expense on capital leases		-			(2,488	)
Bank charges		(483	)		(14,785	)
Net Profit (Loss) Before Reorganization Items	$	1,978		$	(2,149,094	)
REORGANIZATION ITEMS					-
Proceed from Sale to Crealta	$	-		$	(116,282,138	)
Distribution to Noteholders	$	1,590,303		$	126,129,253
Professional Fees		1,054,078			11,560,994
Cure Cost		-			(2,393,690	)
Accrual Adjustments (Changes in estimates)		-			(901,303	)
U. S. Trustee Quarterly Fees		-			13,325
Interest Earned on Accumulated Cash from Chapter 11 (see continuati		-			-
Gain (Loss) from Sale of Equipment		-			(3,046,863	)
Impairment of Assets		1,569,540			1,569,540
Total Reorganization Expenses	$	4,213,921		$	16,649,118
Income Taxes					-
Net Profit (Loss)	$	(4,211,943	)	$	(18,798,212	)

*“Insider” is defined in 11 U.S.C. Section 101(31).

SAVIENT_MOR_2

FORM MOR-2

(04/07)


In re: Savient Pharmaceuticals, Inc., et al				Case No. 13-12680 (MFW)
Debtor				Reporting Period: February 1, 2014 - February 28, 2014

SPHI (13-12681): STATEMENT OF OPERATIONS

(Income Statement)


REVENUES	For The Month Ended February 28, 2014			Cumulative Filing to Date October 15, 2013 Through February 28, 2014
NOT APPLICABLE	$	-		$	-
				$	-
COST OF GOODS SOLD					-
NOT APPLICABLE	$	-		$	-
				$	-
OPERATING EXPENSES (NONE NOTED FOR THE CURRENT PERIOD)					-
				$	-
General and Administrative Related Expenses:					-
Compensation and related benefits and taxes	$	-		$	-
Share-based compensation		-			-
Accrued sales commissions (SFAS 123-R expense)		-			-
Insurance (Amortization of prepaid insurance)		-			-
Travel and entertainment		-			-
Occupancy		-			-
Outside consulting services		-			-
General expenses and office supplies		945			945
Accrued Board of Directors’ cash payments		-			-
Communications (Utilities)		-			-
Legal expenses		-			-
Corporate communications and investor relations		-			-
Total General and Administrative Related Expenses:	$	945		$	945
Total Operating Expenses Before Depreciation	$	945		$	945
Depreciation and amortization		-			-
Net Loss Before Other Income & Expenses	$	(945	)	$	(945	)
					-
OTHER INCOME AND (EXPENSES)					-
Dividend income	$	-		$	76
Interest Expense on capital leases		-			-
Bank charges		-			(20	)
Net Profit (Loss) Before Reorganization Items	$	(945	)	$	(889	)
REORGANIZATION ITEMS					-
Impairment of intercompany note receivable from Parent (Savient)	$	-		$	13,700,356
		-			-
Total Reorganization Expenses	$	-		$	13,700,356
Income Taxes		-			-
Net Profit (Loss)	$	(945	)	$	(13,701,245	)

*“Insider” is defined in 11 U.S.C. Section 101(31).

SPHI_MOR 2

FORM MOR-2

(04/07)


In re: Savient Pharmaceuticals, Inc., et al		Case No. 13-12680 (MFW)
Debtor		Reporting Period: February 1, 2014 - February 28, 2014

SAVIENT (13-12680): BALANCE SHEET


ASSETS	BOOK VALUE AT FEBRUARY 28, 2014		BOOK VALUE ON PETITION DATE
CURRENT ASSETS
Cash and cash equivalents
Petty cash	$	1,000	$	1,000
PNC Bank business operating account		5,053,209		4,207,573
PNC AR Lockbox		543,809
Wells Fargo utilities account		14,228		-
Fidelity U.S. Treasury money market account		-		383,689
Wells Fargo money market account		6,209,254		3,169,442
PNC Letter of Credit (Acct # 31900362019 - Secure the LOC)		1,304,340		1,304,340
PNC Letter of Credit (Acct #31800362548 - Covers LOC Fees)		150,222		150,222
Total cash and cash equivalents	$	13,276,062	$	9,216,266

Short-term investments
Wells Fargo CD Portfolio	$	-	$	3,039,116
Total short-term investments	$	-	$	3,039,116
				-
Accounts receivable (Net)	$	4,884,101	$	7,088,730
Inventories (Net)	$	-	$	1,208,192

Prepaid expenses and other current assets
Prepaid D&O insurance	$	2,129,611	$	2,603,465
Professional retainers		933,427		1,552,562
Other receivables non-trade		291,208		622,746
Prepaid-other		85,616		313,115
Prepaid-other insurance		99,202		221,089
Prepaid rent		9,667		65,698
Prepaid marketing costs (YNF- Co-pay program)		-		83,424
Prepaid product liability insurance		-		96,338
Advances to employees		600		600
Total prepaid expenses and other current assets	$	3,549,331	$	5,559,037

TOTAL CURRENT ASSETS	$	21,709,494	$	26,111,341
PROPERTY AND EQUIPMENT
Office equipment	$	-	$	656,229
Other furniture and fixtures		-		6,005
Leasehold Improvements		-		1,496,216
Capital lease assets		-		212,770
Less Accumulated Depreciation		-		(684,933	)
TOTAL PROPERTY & EQUIPMENT	$	-	$	1,686,287
OTHER ASSETS
Investment in wholly-owned subsidiary (Savient Pharma Holdings, SPHI)	$	147,259,564	$	147,259,564
Investment in wholly-owned subsidiary (Savient Pharma Ireland, Limited, SPIL)		134		134
TOTAL OTHER ASSETS	$	147,259,698	$	147,259,698

TOTAL ASSETS	$	168,969,192	$	175,057,326

SAVIENT_MOR_3

FORM MOR-3

(04/07)


LIABILITIES AND OWNER EQUITY	BOOK VALUE AT FEBRUARY 28, 2014			BOOK VALUE ON PETITION DATE
*LIABILITIES NOT SUBJECT TO COMPROMISE (Postpetition)*
Accounts payable	$	11,357		$	12,972
Accrued expenses
Accrued professional fees	$	6,874,205		$	-
Accrued employee expense reimbursement		-			13,093
Other accrued postpetition liabilities (see attached schedule)		90,287			-
Total accrued expenses	$	6,964,492		$	13,093

Other liabilities not subject to compromise
Accrued royalties payable	$	-		$	943,189
Deferred revenue		-			936,535
Reserve for returns		-			407,355
Reserve for chargeback’s		30,023			264,528
Reserve for Medicaid claims		305,047			241,584
Capital lease liability		-			185,672
Accrued distribution fees		32,033			44,528
Accrued Delaware franchise taxes		38,920			58,380
Accrued sales and use taxes		3,424			-
Accrued payroll taxes (Puerto Rico)		-			-
Total other liabilities not subject to compromise	$	409,447		$	3,081,771

TOTAL LIABILITIES NOT SUBJECT TO COMPROMISE (POSTPETITION LIABILITIES)	$	7,385,296		$	3,107,836
*LIABILITIES SUBJECT TO COMPROMISE (Pre-Petition)*
Accounts payable	$	849,096		$	1,402,335
Accrued expenses
Other accrued pre-petition liabilities (see attached schedule)	$	1,239,587		$	1,818,953
Total accrued expenses	$	1,239,587		$	1,818,953

Other liabilities subject to compromise
Senior Secured 2019 Notes	$	144,257,695		$	144,257,695
Subordinated Debt 2018 Convertible Notes		99,555,240			99,555,240
Intercompany loan payable to wholly owned subsidiary Savient Pharma Holdings, SPHI		29,204,944			15,504,588
Accrued Purchase commitment reserve		-			3,771,066
Accrued Severance liability		2,102,695			2,102,695
Warrant Liability		1,479,776			1,479,776
Accrued home office bonuses		1,370,749			1,370,749
Accrued Sales commissions		733,400			820,357
Embedded conversion features liability 2018 convertible notes		848,100			848,100
Accrued retention bonuses		821,030			821,030
Accrued vacation		-			281,395
Employee benefit related (flex spending liabilities)		-			50,597
Total other liabilities subject to compromise	$	280,373,629		$	270,863,288

TOTAL LIABILITIES SUBJECT TO COMPROMISE (PRE-PETITION)	$	282,462,312		$	274,084,576

TOTAL LIABILITIES	$	289,847,608		$	277,192,412
*OWNER EQUITY*
Common Stock	$	736,949		$	736,949
Additional Paid-In Capital		401,437,969			400,739,096
Retained Earnings - Pre-Petition		(504,255,122	)		(503,611,131	)
Retained Earnings - Postpetition		(18,798,212	)
NET OWNER EQUITY	$	(120,878,416	)	$	(102,135,086	)

TOTAL LIABILITIES AND OWNERS’ EQUITY	$	168,969,192		$	175,057,326


*“Insider” is defined in 11 U.S.C. Section 101(31).		-

SAVIENT_MOR_3

FORM MOR-3

(04/07)


In re: Savient Pharmaceuticals, Inc., et al		Case No. 13-12680 (MFW)
Debtor		Reporting Period: February 1, 2014 -February 28, 2014

SPHI (13-12681): BALANCE SHEET


ASSETS	BOOK VALUE AT FEBRUARY 28, 2014			BOOK VALUE ON PETITION DATE
CURRENT ASSETS
Cash and cash equivalents
PNC Bank business operating account		3,240,642			3,241,604
Fidelity U.S. Treasury money market account		-			13,700,283
Total cash and cash equivalents	$	3,240,642		$	16,941,887

TOTAL CURRENT ASSETS	$	3,240,642		$	16,941,887

TOTAL ASSETS	$	3,240,642		$	16,941,887

*OWNER EQUITY*
Common Stock	$	1		$	1
Additional Paid-In Capital		147,259,563			147,259,563
Retained Earnings - Pre-Petition		(130,317,677	)		(130,317,677	)
Retained Earnings - Postpetition		(13,701,245	)		-
NET OWNER EQUITY	$	3,240,642		$	16,941,887

TOTAL LIABILITIES AND OWNERS’ EQUITY	$	3,240,642		$	16,941,887

SPHI_MOR_3

FORM MOR-3

(04/07)


In re: Savient Pharmaceuticals, Inc., et al		Case No. 13-12680 (MFW)
Debtor		Reporting Period: February 1, 2014 - February 28, 2014

SAVIENT (13-12680): STATUS OF POSTPETITION TAXES

All postpetition taxes were current as of February 28, 2014 and paid in the ordinary course by the Debtor.

SUMMARY OF UNPAID POSTPETITION DEBTS

As reflected below, Debtor is current on all postpetition debts.


	Number of Days Past Due
	Current		0-30		31-60		61-90		Over 90		Total
Accounts Payable	$	2,194	$	1,725	$	7,438	$	-	$	-	$	11,357
Employee Expenses Payable (Concur)		-		-		-		-		-	$	-
Wages Payable		-		-		-		-		-		-
Taxes Payable		-		-		-		-		-		-
Rent/Leases-Building		-		-		-		-		-		-
Rent/Leases-Equipment		-		-		-		-		-		-
Secured Debt/Adequate Protection Payments		-		-		-		-		-		-
Professional Fees		-		-		-		-		-		-
Amounts Due to Insiders		-		-		-		-		-		-
Total Postpetition Debts	$	2,194	$	1,725	$	7,438	$	-	$	-	$	11,357

SAVIENT_MOR_4

FORM MOR-4

(04/07)


In re: Savient Pharmaceuticals, Inc., et al		Case No. 13-12680 (MFW)
Debtor		Reporting Period: February 1, 2014 - February 28, 2014

SPHI (13-12681): STATUS OF POSTPETITION TAXES

All postpetition taxes were current as of February 28, 2014 and paid in the ordinary course by the Debtor.

SUMMARY OF UNPAID POSTPETITION DEBTS

The Debtor is current on all postpetition debts.

SPHI_MOR_4

FORM MOR-4

(04/07)


In re: Savient Pharmaceuticals, Inc., et al		Case No. 13-12680 (MFW)
Debtor		Reporting Period: February 1, 2014 - February 28, 2014

SAVIENT (13-12680): ACCOUNTS RECEIVABLE RECONCILIATION AND AGING


Accounts Receivable Reconciliation	BOOK VALUE AT FEBRUARY 28, 2014			BOOK VALUE AT JANUARY 31, 2014			BOOK VALUE AT DECEMBER 31, 2013			BOOK VALUE AT NOVEMBER 30, 2013			BOOK VALUE AT OCTOBER 31, 2013
Total Accounts Receivable at the beginning of the reporting period	$	5,936,972		$	7,434,952		$	7,372,339		$	7,116,283			7,045,577
+ Amounts billed during the period		-			1,162,843			3,365,207			2,570,042			2,177,755
- Amounts collected during the period		(1,030,335	)		(2,168,659	)		(2,294,795	)		(1,243,215	)		(1,455,908	)
- Discounts and Chargeback’s		(7,748	)		(457,211	)		(953,422	)		(1,036,869	)		(600,708	)
- Return Credits		-			(5,037	)		(19,364	)		(2,551	)		(20,378	)
- Prompt Pay Discounts		(14,788	)		(29,916	)		(35,013	)		(31,351	)		(30,055	)
Total Accounts Receivable at the end of the reporting period	$	4,884,101		$	5,936,972		$	7,434,952		$	7,372,339		$	7,116,283
- Provision for discounts		-			-			(49,626	)		(34,907	)		(59,679	)
+ Accounts receivable other		-			73,838			67,200			47,612			22,795
Total Accounts Receivable, Net at the end of the reporting period	$	4,884,101		$	6,010,810		$	7,452,526		$	7,385,044		$	7,079,399

Accounts Receivable Aging	BOOK VALUE AT FEBRUARY 28, 2014			BOOK VALUE AT JANUARY 31, 2014			BOOK VALUE AT DECEMBER 31, 2013			BOOK VALUE AT NOVEMBER 30, 2013			BOOK VALUE AT OCTOBER 31, 2013
0 - 30 days old	$	995,123		$	2,815,441		$	4,635,949		$	5,679,858			5,672,068
31 - 60 days old		781,474			315,136			1,177,031			263,279			-
61 - 90 days old		420,865			1,125,299			187,404			6,427			21,440
91+ days old		2,686,639			1,681,095			1,434,568			1,422,775			1,422,775
Total Accounts Receivable at the end of the reporting period	$	4,884,101		$	5,936,972		$	7,434,952		$	7,372,339		$	7,116,283
- Provision for discounts		-			-			(49,626	)		(34,907	)		(59,679	)
+ Accounts receivable other		-			73,838			67,200			47,612			22,795
Total Accounts Receivable, Net at the end of the reporting period	$	4,884,101		$	6,010,810		$	7,452,526		$	7,385,044		$	7,079,399
DEBTOR QUESTIONNAIRE
Must be completed each month	Yes			No
1. Have any assets been sold or transferred outside the normal course of business this reporting period? If yes, provide an explanation below.		X*
2. Have any funds been disbursed from any account other than a debtor in possession account this reporting period? If yes, provide an explanation below.					X
3. Have all postpetition tax returns been timely filed? If no, provide an explanation below.					X**
4. Are workers compensation, general liability and other necessary insurance coverages in effect? If no, provide an explanation below.		X
5. Has any bank account been opened during the reporting period? If yes, provide documentation identifying the opened account(s). If an investment account has been opened provide the required documentation pursuant to the Delaware Local Rule 4001-3.					X

*Assets were sold outside the ordinary course of business pursuant to Court order [Docket No. 434].

**Debtor is in the process of filing returns that were due in February 2014.

SAVIENT_MOR_5

FORM MOR-5

(04/07)


In re: Savient Pharmaceuticals, Inc., et al		Case No. 13-12680 (MFW)
Debtor		Reporting Period: February 1, 2014 - February 28, 2014

SPHI(13-12681): ACCOUNTS RECEIVABLE RECONCILIATION AND AGING


Accounts Receivable Reconciliation		Amount
NOT APPLICABLE		$ -

Accounts Receivable Aging		Amount
NOT APPLICABLE		$ -

DEBTOR QUESTIONNAIRE
Must be completed each month		Yes	No
1.	Have any assets been sold or transferred outside the normal course of business this reporting period? If yes, provide an explanation below.		X
2.	Have any funds been disbursed from any account other than a debtor in possession account this reporting period? If yes, provide an explanation below.		X
3.	Have all postpetition tax returns been timely filed? If no, provide an explanation below.	X
4.	Are workers compensation, general liability and other necessary insurance coverages in effect? If no, provide an explanation below.	X
5.	Has any bank account been opened during the reporting period? If yes, provide documentation identifying the opened account(s). If an investment account has been opened provide the required documentation pursuant to the Delaware Local Rule 4001-3.		X

SPHI_MOR_5

FORM MOR-5

(04/07)

In re: Savient Pharmaceuticals, Inc., et al

Case No. 13-12680 (MFW)

Reporting Period: February 1, 2014 - February 28, 2014

SAVIENT (13-12680): SCHEDULE OF CASH RECEIPTS AND DISBURSEMENTS

SAVIENT PHARMACEUTICALS INC 8-K